Valproate for the Treatment of Residual Amblyopia

The goal of this clinical trial is to determine the efficacy of valproate as an adjunct therapy to treat amblyopia beyond the critical period in children aged 8-17 years who have amblyopia of ≥3 lines of interocular best-corrected (with glasses) visual acuity difference. The main questions it aims to answer are: * Does valproate enable clinically meaningful and durable visual recovery from amblyopia? * Do valproate-treated patients show a change in amblyopic eye visual acuity (lines)? Participants will undergo daily patching for 2 hours (standard of care) plus the addition of valproate or placebo for a total of 16 weeks.

NCT Number	NCT07226141
Lead Sponsor	Boston Children's Hospital
Conditions	Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Enrollment	28 participants
Start Date	2026-07-01
Primary Completion	2027-09-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-30